Advanced search
Publication Cover
Journal of Pain & Palliative Care Pharmacotherapy Volume 38, 2024 - Issue 1
Submit an article Journal homepage
711
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Use of Fosaprepitant for Management of Suspected Antimicrobial-Associated Nausea: A Case Report

Brandon Perkovicha Division of Geriatrics, Gerontology and Palliative Care, University of California San Diego, La Jolla, California, USA.View further author information
, MD MBA,
Rabia S. Atayeea Division of Geriatrics, Gerontology and Palliative Care, University of California San Diego, La Jolla, California, USA.;b Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA;c San Diego Health, Department of Pharmacy, University of California, San Diego, La Jolla, California, USAView further author information
, PharmD, BCPS, APh, FAAHPM,
Jennifer S Kima Division of Geriatrics, Gerontology and Palliative Care, University of California San Diego, La Jolla, California, USA.View further author information
, NP, ACHPN &
Tamara Rubenzika Division of Geriatrics, Gerontology and Palliative Care, University of California San Diego, La Jolla, California, USA.;d Division of Nephrology and Hypertension, University of California San Diego, La Jolla, California, USACorrespondence[email protected]
View further author information
, MD
Pages 28-32 | Received 06 Sep 2023, Accepted 05 Nov 2023, Published online: 20 Nov 2023

References

  • Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59. doi:10.2147/CIA.S13109.
  • Leach C. Nausea and vomiting in palliative care. Clin Med (Lond). 2019;19(4):299–301. doi:10.7861/clinmedicine.19-4-299.
  • Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ. 1998;158(13):1717–26.
  • Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986–92. doi:10.1093/annonc/mds021.
  • Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497–503. doi:10.1007/s00520-006-0173-z.
  • Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97(11):2880–6. doi:10.1002/cncr.11408.
  • Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261–8. doi:10.1002/cncr.20230.
  • Janssen DJ, Spruit MA, Wouters EF, Schols JM. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med. 2008;22(8):938–48. doi:10.1177/0269216308096906.
  • Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58–69. doi:10.1016/j.jpainsymman.2005.06.007.
  • Ibrahim MA, Preuss CV. Antiemetic neurokinin-1 receptor blockers. [Updated 2023 Mar 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470394/
  • Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27(1):172–8. doi:10.1093/annonc/mdv482.
  • Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002;94(11):3032–41. doi:10.1002/cncr.10516.
  • Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29(11):1495–501. doi:10.1200/JCO.2010.31.7859.
  • Merck and Company, Incorporated. Emend (fosaprepitant) [package insert]. U.S. Food and Drug Administration website. [cited 2018 Apr; accessed 2023 Jun 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022023s017lbl.pdf.
  • Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–97. Epub 2020 Jul 13. Erratum in: j Clin Oncol. 2020 Nov 10;38(32):3825. Erratum in: J Clin Oncol. 2021 Jan 1;39(1):96. doi:10.1200/JCO.20.01296.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.